Bladder carcinoma following cyclophosphamide therapy. A case report.
Cyclophosphamide was introduced in 1958 in an effort to minimize the side effects of nitrogen mustard. Cyclophosphamide (Cytoxan, Endoxan) is not an alkylating agent which has been used for the treatment of a variety of non-malignant as well as malignant diseases. It has also recently been the focus of considerable interest as an immunosuppressive agent, perhaps the most potent immunosuppressive drug that has been synthesized. Reports of urologic complications from this drug are haemorrhagic cystitis, vesical fibrosis and urothelial carcinoma.
D000328:Adult; D002295:Carcinoma, Transitional Cell / Q000139:chemically induced* / Q000473:pathology; D003520:Cyclophosphamide / Q000009:adverse effects*; D006801:Humans; D008297:Male; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced* / Q000473:pathology
D003520:Cyclophosphamide